Keyphrases
Anti-PCSK9 Monoclonal Antibodies
12%
Antisense
100%
Antisense Therapy
37%
Apolipoprotein A-I (ApoA-I)
62%
Apolipoprotein B (Apo B)
50%
Apolipoprotein(a)
12%
Cardiovascular Disease
12%
Clinical Practice
12%
Ezetimibe
12%
Information Collection
12%
Lifestyle Intervention
12%
Lines of Evidence
12%
Lipoprotein Apheresis
12%
Lipoproteins
100%
Low-density Lipoprotein
25%
Low-density Lipoprotein Particle
12%
Medical Treatment
12%
Metabolism
12%
Nicotinic Acid
12%
Phase II Study
12%
Significant Risk Factors
12%
Standard of Care
12%
Statins
25%
Therapeutic Potential
12%
Medicine and Dentistry
Antisense
100%
Antisense Therapy
37%
Apolipoprotein
12%
Apolipoprotein B
50%
Cardiovascular Disease
12%
Combination Therapy
12%
Ezetimibe
12%
Lifestyle Intervention
12%
Lipoprotein
100%
Lipoprotein Apheresis
12%
Low-Density Lipoprotein
37%
Monoclonal Antibody
12%
Niacin
12%
Statin
25%
Biochemistry, Genetics and Molecular Biology
Antisense
100%
Apheresis
11%
Apolipoprotein
11%
Apolipoprotein B
44%
Lipoprotein
100%
Low-Density Lipoprotein
33%
Metabolic Pathway
11%
Monoclonal Antibody
11%
Niacin
11%
PCSK9
11%
Statin
22%
Pharmacology, Toxicology and Pharmaceutical Science